Search
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64040,L64041] It is taken by mouth once daily.
Helium
go.drugbank.com/drugs/DB09155ApprovedInvestigationalVet approvedHelium is a second most abundant chemical element in the universe with symbol He and atomic number 2. It is a colorless, odorless, tasteless, non-toxic, inert, monatomic gas located at the top of the noble gases on the periodic table. It...
Bepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activi...
Magnesium silicate
go.drugbank.com/drugs/DB13249ApprovedWithdrawnMagnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O. It is known as talc ...
Lorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Beclomethasone dipropionate
go.drugbank.com/drugs/DB00394ApprovedInvestigationalBeclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) ...
Bisoprolol
go.drugbank.com/drugs/DB00612ApprovedInvestigationalBisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure. It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive dr...
IDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
VLTS-934
go.drugbank.com/drugs/DB05597InvestigationalVLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).